Saccharomyces boulardii

Saccharomyces boulardii is the only yeast formally recognized as a probiotic and the only probiotic with regulatory approval as a pharmaceutical drug in several countries for the treatment of acute infectious diarrhea and antibiotic-associated diarrhea.

Supplied as a lyophilized or spray-dried powder with viability between 10 and 50 billion CFU per gram at release. Because S. boulardii is a yeast (not a bacterium), it is intrinsically resistant to antibiotics, making it the probiotic of choice for concurrent antibiotic therapy.

Beige to light brown free-flowing powder with a faintly yeasty note. Particle size suitable for capsule filling, sachet blending, and chewable formats.

We supply food-grade and pharmaceutical-grade Saccharomyces boulardii from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to yeast probiotic production.

Common market grades include 10, 20, and 50 billion CFU per gram freeze-dried and spray-dried powders, with spray-dried grades offering room-temperature shelf stability for capsule and sachet formats. Pharmaceutical-grade material is supplied under additional pharmacopoeial release criteria. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.

Saccharomyces boulardii was isolated from the skin of lychee and mangosteen fruits in Indochina in 1923 by French microbiologist Henri Boulard, who observed local populations using the fruit decoction to manage cholera-associated diarrhea. The reference commercial strain CNCM I-745 has been continuously cultivated and commercialized since the 1940s by Biocodex under the Florastor and Ultra-Levure brands.

Industrial production uses molasses- or glucose-based fermentation under aerobic conditions, biomass recovery by centrifugal separation, washing, cryoprotectant blending, and either lyophilization or spray drying. Spray-dried product is room-temperature stable, which is a significant commercial advantage over bacterial probiotics.

Regulatory status is unique. The strain is approved as a pharmaceutical drug in France, Italy, and several other European countries; available as a prescription and over-the-counter medication; and marketed as a dietary supplement in the United States with GRAS notification GRN 877. EFSA Qualified Presumption of Safety status applies.

Clinical evidence is the strongest of any probiotic: multiple meta-analyses confirm efficacy for prevention of antibiotic-associated diarrhea (number needed to treat approximately 10) and for shortening the duration of acute infectious diarrhea in children. Evidence for C. difficile recurrence prevention as an adjunct to standard therapy is also well-supported.

S. boulardii is positioned as the premium clinical probiotic in pharmacy and supplement channels worldwide and is the default choice for concurrent antibiotic use.

• Capsules and sachets for acute infectious diarrhea
• Antibiotic-associated diarrhea prevention and management
• Travelers diarrhea prevention
• Clostridioides difficile recurrence prevention as adjunct
• Pediatric probiotic drops and sachets
• IBS and inflammatory bowel symptom support
• Helicobacter pylori eradication adjunct therapy
• Functional foods requiring antibiotic-compatible probiotic
• Animal feed and veterinary probiotic products